Jefferies downgrades Mesoblast stock to Hold despite price target increase

Jefferies downgraded Mesoblast (MESO) to Hold from Buy, despite a modest price target increase to AUD2.60, following the release of its Q4 FY2025 unaudited results which detailed initial Ryoncil sales of US$13.2 million gross from its late-March launch. This downgrade, occurring despite MESO's 73.8% annual return and a projected 226% FY2025 revenue growth, suggests Jefferies is cautious on the early commercialization trajectory and weak gross margins, preceding the full FY2025 financial results due August 27.

Analysis

Jefferies has downgraded Mesoblast Limited (MESO) from Buy to Hold, a cautious move that contrasts with a minor price target increase to AUD2.60. This decision follows the release of preliminary Q4 FY2025 results, which reported US$13.2 million in unaudited gross revenue from the new drug Ryoncil between its March 28 launch and June 30, 2025. Jefferies interprets these figures as representing approximately 68 paid infusions and an estimated net revenue of US$10 million, suggesting a measured view on the initial commercialization ramp-up. The downgrade comes despite the stock's strong historical performance, evidenced by a 73.8% return over the past year, and a very high forward-looking revenue growth forecast of 226% for FY2025. The core concern appears to stem from the company's weak gross profit margins, a key metric that tempers the optimistic top-line projections. The full audited financial results, scheduled for release on August 27, 2025, will be a critical data point for validating Ryoncil's early sales trajectory and profitability.

Key Decisions for Investors

• Investors should view the Jefferies downgrade to Hold as a signal of near-term caution, suggesting the initial Ryoncil sales ramp and weak gross margins may not justify a more bullish stance despite high revenue growth forecasts.
• The full financial results on August 27, 2025, represent a significant catalyst; focus should be on the detailed sales breakdown, net revenue figures, and particularly any commentary on improving gross profit margins.
• Given the stock's 73.8% past-year return juxtaposed with the analyst's concerns, MESO presents a speculative growth profile where potential investors must weigh the high top-line potential against significant execution risks in its early commercialization phase.